Prasugrel News and Research

RSS
MADONNA: Personalized antiplatelet therapy savior for angioplasty patients?

MADONNA: Personalized antiplatelet therapy savior for angioplasty patients?

AstraZeneca’s ticagrelor receives Class I recommendation from ESC

AstraZeneca’s ticagrelor receives Class I recommendation from ESC

Personalized antiplatelet treatment leads to better outcomes in patients undergoing PCI

Personalized antiplatelet treatment leads to better outcomes in patients undergoing PCI

Prasugrel as safe as clopidogrel in preventing heart attack, stroke and death

Prasugrel as safe as clopidogrel in preventing heart attack, stroke and death

HCRI announces successful completion of randomization in DAPT Study

HCRI announces successful completion of randomization in DAPT Study

Ticagrelor ‘now on equal footing’ with other antiplatelets

Ticagrelor ‘now on equal footing’ with other antiplatelets

Ticagrelor ‘now on equal footing’ with other antiplatelets

Ticagrelor ‘now on equal footing’ with other antiplatelets

JRD receives FDA priority review designation for XARELTO sNDAs to treat PE, DVT

JRD receives FDA priority review designation for XARELTO sNDAs to treat PE, DVT

Janssen receives FDA complete response letter for XARELTO sNDA

Janssen receives FDA complete response letter for XARELTO sNDA

Janssen submits XARELTO sNDA with FDA to reduce risk of stent thrombosis in ACS patients

Janssen submits XARELTO sNDA with FDA to reduce risk of stent thrombosis in ACS patients

Aggredyne closes $3 million Series A convertible preferred stock financing

Aggredyne closes $3 million Series A convertible preferred stock financing

The Lancet acknowledges world's first bedside genetic test

The Lancet acknowledges world's first bedside genetic test

CRF initiates Harmonizing Outcomes with Revascularization and Stents in AMI II trial

CRF initiates Harmonizing Outcomes with Revascularization and Stents in AMI II trial

CVD/MI complications tend to occur within first 30 days after PCI

CVD/MI complications tend to occur within first 30 days after PCI

FDA assigns Priority Review designation to JRD's XARELTO sNDA

FDA assigns Priority Review designation to JRD's XARELTO sNDA

The Chinese acute coronary syndrome drug market to grow from $326M in 2010 to $448M in 2015

The Chinese acute coronary syndrome drug market to grow from $326M in 2010 to $448M in 2015

NYU Langone cardiovascular experts present new research findings at AHA 2011

NYU Langone cardiovascular experts present new research findings at AHA 2011

Accumetrics VerifyNow test shows patients with high PRU exhibit higher stent thrombosis

Accumetrics VerifyNow test shows patients with high PRU exhibit higher stent thrombosis

Tailored anti-platelet therapy optimizes treatment for patients wtih common genetic variant

Tailored anti-platelet therapy optimizes treatment for patients wtih common genetic variant

HCRI completes enrollment in dual antiplatelet therapy clinical trial

HCRI completes enrollment in dual antiplatelet therapy clinical trial